Meta's advertising algorithm cannot distinguish between a compounding pharmacy and a drug manufacturer. It sees the words semaglutide, tirzepatide, and BPC-157 and applies the pharmaceutical advertising policy. The same policy that governs Pfizer and Novo Nordisk. Your compounding pharmacy is not a manufacturer. But Meta does not know that unless you make it explicit.
We have managed ad accounts for compounding pharmacies since 2023. The core problem is always the same: Meta treats compounding as drug manufacturing and bans the account under its prescription drug policy. The solution is building a compliance framework that tells Meta's review systems exactly what you are and what you are not.
Compounding vs Manufacturing and Why Meta Gets It Wrong
The FDA draws a clear line between compounding and manufacturing. Compounding pharmacies prepare medications for individual patients based on prescriptions. They operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. They are regulated by state pharmacy boards, not by the FDA's drug approval process. Their products are not FDA-approved because they are not supposed to be. They are patient-specific preparations.
Drug manufacturers operate under Section 505 of the FD&C Act. They produce medications at scale for distribution, not for individual patients. They require FDA approval through the New Drug Application process. Meta's advertising policy treats anyone mentioning drug names as a manufacturer subject to prescription drug advertising restrictions.
FDA 503A and 503B Explained for Advertisers
Section 503A governs traditional compounding pharmacies. These facilities compound medications for individual patients with valid prescriptions. They can only use FDA-approved bulk drug substances or substances with a USP monograph. They cannot compound drugs that are copies of commercially available FDA-approved products. The FDA inspects 503A facilities through state pharmacy board agreements.
Section 503B created outsourcing facilities in 2013 after the New England Compounding Center tragedy. These facilities can produce larger batches of compounded medications for office use by hospitals and clinics. They register with the FDA directly, follow Current Good Manufacturing Practice requirements, and are subject to FDA inspections. A 503B facility has a valid FDA Establishment Identifier, which is the single most important document to include in your Meta appeal.
If your pharmacy has 503B registration, lead with that in your business verification and appeals. It shows Meta's review team that you operate under FDA oversight with CGMP compliance.
The BAV Appeal Pathway
Meta's Business Account Verification appeal process is the only pathway that works for compounding pharmacies. The standard ad account appeal through Account Quality typically fails because the reviewer applies the prescription drug policy without understanding the compounding distinction.
The BAV appeal requires specific documentation. Submit your state pharmacy board license. If you have 503B registration, include your FDA Establishment Identifier certificate. Include your pharmacy's NPI number and DEA registration. These documents establish that you are a licensed healthcare provider, not an unregulated supplement seller or illicit drug promoter.
DSHEA 1994 and Compound Advertising
Compounded medications are not dietary supplements. This matters because DSHEA 1994 does not protect compound advertising. DSHEA allows structure-function claims for supplements. Compounded drugs are pharmaceuticals subject to FDA prescription drug labeling requirements.
The practical implication for Meta advertising: do not use supplement-style marketing for compounded medications. Do not mention weight loss outcomes. Do not use before-and-after imagery. Do not reference research studies. Position your ads as informational about your pharmacy's services, not about the effects of specific compounds.
Compounding Pharmacy Restored in 6 Days
A Florida compounding pharmacy with 503A registration had their Meta account banned after running ads for peptide therapy services. The ban notice cited Prescription Drug Policy violation. The account had been active for four months with moderate spend.
We identified the issue immediately: their ad copy mentioned semaglutide for weight loss, which Meta's system flagged as pharmaceutical advertising. Their landing page also listed pricing for specific compounded medications, which Meta treats as online pharmacy activity requiring additional verification.
We rewrote the ad copy to focus on the pharmacy's compounding services and the medical supervision model, without naming specific medications. We restructured the landing page to describe service categories rather than specific drug pricing. We filed the BAV appeal with the pharmacy's Florida Board of Pharmacy license, DEA registration, and NPI documentation. The account was reinstated in 6 days.
Building a Meta-Compliant Compounding Landing Page
Your landing page structure matters more than your ad copy. We recommend a four-section layout that Meta's review system can parse cleanly.
Section one: your pharmacy's credentials. State license, DEA registration, 503A or 503B status, and supervising pharmacist information. This tells the automated review system you are a licensed healthcare entity.
Section two: your compounding process. Explain how you compound medications per individual prescriptions with physician oversight. Use language like patient-specific preparations based on valid prescriptions , this mirrors FDA 503A language and signals legitimacy.
Section three: the conditions you serve. List therapeutic categories like hormone therapy, peptide therapy, and pain management, without naming specific medications. Meta's system triggers on drug names, not on condition categories.
Section four: the patient onboarding process. Describe the medical consultation, prescription requirement, and follow-up care. This demonstrates a clinical relationship rather than direct-to-consumer drug sales.
Ready to Reinstate Your Compounding Ads?
We have reinstated compounding pharmacy ad accounts on Meta, Google, and TikTok. Our approach combines FDA regulatory knowledge with platform-specific appeal strategies. If your compounding pharmacy ads were banned, we can audit your account, identify the specific policy trigger, and file a structured appeal with the right documentation.
Book a free account audit → calendly.com/custodio-2/30min